Navigation Links
Pulmo BioTech Announces an Increase in its Stake in PulmoScience
Date:5/9/2008

ng technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible t
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
2. Pulmo BioTech Announces Appointment of Chief Financial Officer
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
5. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology
8. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
9. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
10. DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members
11. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... University of Wisconsin-Madison researchers led by stem-cell pioneer ... cultures under cleaner and better-defined lab conditions than ... journal Nature Biotechnology, could pave the way for ... because of animal-cell contamination. Growing stem cells in ...
... continues to make stem-cell advances , such as ... things aren't going so well elsewhere in the world: ... South Korean stem-cell researcher, fell from grace in just ... stem-cell research results. , ,Originally, the allegations against him ...
... the original story was based on an official summary that referred ... certain amendments. Under the law as enacted, the source code would ... analyzed in the case of a recount, but not open to ... it may have caused. , , Madison, Wis. ...
Cached Biology Technology:Stem-cell controversies slow progress 2Voting machine source code must be available for review 2
(Date:7/10/2014)... chronic inflammatory skin diseases psoriasis* and eczema** are similar ... to base their decision on which treatment should be ... tissue samples. A team of researchers at the Helmholtz ... have now analyzed the molecular processes that occur in ... them for the first time to gain a detailed ...
(Date:7/10/2014)... July 10, 2014Women in the West African nation ... family planning option. Sayana Press has the potential ... of the health system and in communities by ... contraceptivePfizer,s Depo-Provera (depot medroxyprogesterone acetate)with the BD Uniject ... of four African countries expected to begin introducing ...
(Date:7/9/2014)... that,s not why the Millennials are eating it, according to ... annual International Recognition Days convention July 10th in Milwaukee. , ... that are quick, easy to cook and that can help ... about any health benefits of Tofu," said lead Cornell researcher ... it,s quick to cook and it,s filling.", The study of ...
Breaking Biology News(10 mins):New diagnostic test to distinguish psoriasis from eczema 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... LA JOLLA, Calif., September 25 2013 A new ... called medulloblastoma has been developed by researchers at Sanford-Burnham ... cellsthe cells that are critical for maintaining tumor growthand ... are essential for tumor progression. The process destroys the ...
... how their meat is sourced, with animal welfare ... many purchases. Unfortunately, many widely-used livestock production methods ... from the University of Cambridge has identified what ... silvopastoral systems which include shrubs and trees with ...
... , Sept. 25, 2013   GenoVive , an innovator ... against the emerging "globesity" epidemic through its development of ... on each individual,s unique metabolism.  "Weight Loss Designed by ... to customize an all natural meal and exercise program ...
Cached Biology News:New approach to treating human brain cancer could lead to improved outcomes 2New approach to treating human brain cancer could lead to improved outcomes 3Sustainable livestock production is possible 2Sustainable livestock production is possible 3"GenoVive is changing the face of personalized health by continuing research efforts with Harvard." 2
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Phospho-FADD (Ser194) Antibody (Human Specific)...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: